Mizuho analyst Anthony Petrone raised the firm’s price target on MiMedx to $10 from $7 and keeps a Buy rating on the shares. The analyst updated medtech and diagnostics price targets ahead of the Q2 reporting season.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDXG:
- MiMedx announces ‘favorable’ ruling in securities class action case
- MiMedx CFO Pete Carlson resigns, Doug Rice to succeed
- MIMEDX Appoints Doug Rice as Chief Financial Officer
- MiMedx CEO buys $640K in common stock as part of option expiry
- MiMedx price target lowered to $8 from $9.50 at H.C. Wainwright